Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC cancer Wong, T. Y., Zhang, K. S., Gandhi, R. T., Collins, Z. S., O'Hara, R., Wang, E. A., Vaheesan, K., Matsuoka, L., Sze, D. Y., Kennedy, A. S., Brown, D. B. 2022; 22 (1): 224

Abstract

BACKGROUND: The goal of this study was to evaluate efficacy and safety of 90Y radioembolization for neuroendocrine liver metastases (NELM) in a multicenter registry.METHODS: One hundred-seventy patients with NELM were enrolled in the registry (NCT02685631). Prior treatments included hepatic resection (n=23, 14%), arterial therapy (n=62, 36%), octreotide (n=119, 83%), cytotoxic chemotherapy (n=58, 41%), biologic therapy (n=49, 33%) and immunotherapy (n=10, 6%). Seventy-seven (45%) patients had extrahepatic disease. Seventy-eight (48%), 61 (37%), and 25 (15%) patients were Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or=2. Tumor grade was known in 81 (48%) patients: 57 (70%) were well-, 12 (15%) moderate-, and 12 (15%) poorly-differentiated. Kaplan-Meier analysis and log rank tests were performed to compare overall and progression-free survival (OS/PFS) by tumor location and grade. Toxicities were reported using Common Terminology Criteria for Adverse Events v.5. Cox Proportional Hazards were calculated for pancreatic primary, performance status, extrahepatic disease at treatment, unilobar treatment, baseline ascites, and>25% tumor burden.RESULTS: One, 2, and 3-year OS rates were 75, 62 and 46%, respectively. Median OS was 33months [(95% CI: 25-not reached (NR)]. The longest median OS was in patients with pancreatic (42months, 95% CI: 33-NR) and hindgut 41months, 95% CI: 12-NR) primaries. The shortest OS was in foregut primaries (26months; 95% CI: 23-NR; X2=7, p=0.1). Median OS of well-differentiated tumors was 36months (95% CI: 10-NR), compared to 44 (95% CI: 7-NR) and 25 (95% CI: 3-NR) months for moderate and poorly differentiated tumors. Median progression-free survival (PFS) was 25months with 1, 2, and 3-year PFS rates of 70, 54, and 35%, respectively. Thirteen patients (7.6%) developed grade 3 hepatic toxicity, most commonly new ascites (n=8, 5%) at a median of 5.5months. Performance status of =2 (HR 2.7, p=0.01) and baseline ascites (HR 2.8, P=0.049) predicted shorter OS.DISCUSSION: In a population with a high incidence of extrahepatic disease, 90Y was effective and safe in treatment of NELM, with median OS of 41months for well differentiated tumors. Grade 3 or greater hepatic toxicity was developed in 7.6% of patients.TRIAL REGISTRATION: NCT02685631 .

View details for DOI 10.1186/s12885-022-09302-z

View details for PubMedID 35232410